slide1 l.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
CUBICIN ® (daptomycin for injection) for S. aureus Bacteremia Including Those With Known or Suspected Endocarditis PowerPoint Presentation
Download Presentation
CUBICIN ® (daptomycin for injection) for S. aureus Bacteremia Including Those With Known or Suspected Endocarditis

Loading in 2 Seconds...

play fullscreen
1 / 37

CUBICIN ® (daptomycin for injection) for S. aureus Bacteremia Including Those With Known or Suspected Endocarditis - PowerPoint PPT Presentation


  • 459 Views
  • Uploaded on

CUBICIN ® (daptomycin for injection) for S. aureus Bacteremia Including Those With Known or Suspected Endocarditis. Anti-Infective Drugs Advisory Committee Meeting March 6, 2006. Staphylococcus aureus Bacteremia . Henry F. Chambers, M.D. Professor of Medicine, UCSF

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'CUBICIN ® (daptomycin for injection) for S. aureus Bacteremia Including Those With Known or Suspected Endocarditis' - Mercy


Download Now An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1

CUBICIN® (daptomycin for injection) for S. aureus Bacteremia Including Those With Known or Suspected Endocarditis

Anti-Infective Drugs Advisory Committee Meeting

March 6, 2006

staphylococcus aureus bacteremia

Staphylococcus aureus Bacteremia

Henry F. Chambers, M.D.

Professor of Medicine, UCSF

Chief of Infectious Diseases

San Francisco General Hospital

case 1
Case 1
  • 38 y/o man, new CHF, alcoholic cardiomyopathy, Hct = 13 (normal 40-45)
  • Given PRBCs, diuretics, afterload reducers
  • HD 6: upper + lower endoscopy
  • Post-procedure T = 39oC, blood cultures taken
  • HD 7: afebrile but BC x2 = GPC in clusters; R forearm former IV site red, tender, indurated
  • Vancomycin administered
  • HD 8: BC isolate = MSSA; f/u BC sterile
management issues
Management Issues
  • What is the risk of a poor outcome?
  • What antibiotic should be used?
  • What is the duration of therapy?
slide5

What is the risk of a poor outcome?

Complications in catheter-associated SAB

Raad, CID 14:75, 1992

independent predictors of complicated sab
Independent Predictors of Complicated SAB

Fowler, Arch Intern Med 163:2066, 2003

what is the risk of a poor outcome
What is the risk of a poor outcome?

1 point each for skin findings, fever > 72h, community onset

4 points for positive blood culture @ 48-96h

Fowler, Arch Intern Med 163:2066, 2003

predictors of poor outcome for staphylococcus aureus bacteremia
Predictors of Poor Outcome for Staphylococcus aureus Bacteremia
  • Septic shock
  • Persistent focus of infection
  • Secondary focus of infection
  • Prolonged bacteremia on therapy (>48-72h)
  • Elderly patient (age > 60 years)
  • MRSA
  • Use of vancomycin instead of a b-lactam
  • Duration of treatment < 10-14 days
criteria for antimicrobial therapy of staphylococcus aureus bacteremia
Criteria for Antimicrobial Therapy of Staphylococcus aureus Bacteremia
  • Bactericidal activity
  • Non-toxic, well-tolerated
  • Parenteral administration, at least initially
  • Convenient dosing
what antibiotic should be used
What antibiotic should be used?

“If the focus of infection has been promptly removed with rapid documented resolution of the bacteremia (< 3 days), 2 weeks of antibiotic therapy with a penicillinase-resistant penicillin, first-generation cephalosporin, or glycopeptideis likely to be enough…..Under no circumstances should patients simply have the catheter removed without antibiotic treatment .”

Antimicrobial Therapy and Vaccines, 2nd Ed., 2002, page 641

what antibiotic should be used12
What antibiotic should be used?

Fowler, CID 27:478-86, 1998

what is the duration of therapy
What is the duration of therapy?

7-10 or fewer days?

  • Associated with high relapse, complication rates

10-14 days?

  • Standard recommended duration

4-6 weeks?

  • For endocarditis, osteomyelitis, complicated SAB
what was done
What was done?
  • PICC placed
  • Ceftriaxone 2g IV q24h for 14 days
  • Home infusion therapy arranged
case 2
Case 2
  • 44 y/o man, homeless, IVDU with fever and back pain, non-localizing exam
  • Vancomycin administered
  • 3/3 BC positive MRSA
  • TTE negative, MRI spine negative
  • Fever persists during first week
  • 1/3 BC + MRSA 72h after admission
slide17

What is the risk of a poor outcome?

Complications in community-onset SAB

Jensen, Arch Intern Med 162: 27, 2003

independent predictors of complicated sab18
Independent Predictors of Complicated SAB

Fowler, et al, Arch Intern Med 163:2066, 2003

independent predictors of complicated sab19
Independent Predictors of Complicated SAB

Fowler, et al, Arch Intern Med 163:2066, 2003

independent predictors of complicated sab20
Independent Predictors of Complicated SAB

Fowler, et al, Arch Intern Med 163:2066, 2003

independent predictors of complicated sab21
Independent Predictors of Complicated SAB

Fowler, et al, Arch Intern Med 163:2066, 2003

what was done23
What was done?
  • PICC placed
  • Methadone maintenance
  • Vancomycin ~1g q12h IV for 6 weeks
  • Trough serum concentrations of ~15 mg/ml
what happened
What happened?
  • Patient returned 3 mo later complaining of back pain
  • Afebrile, normal exam
  • Blood cultures negative
  • MRI: T10-T11 osteomyelitis, discitis
  • Bone biopsy culture: MRSA
what was done25
What was done?
  • PICC placed
  • Methadone maintenance
  • Vancomycin ~1g q12h IV for 6 weeks
  • Trough serum concentrations or ~15 mg/ml
management issues26
Management Issues
  • Is this a vancomcyin failure?
  • Is so, why did it fail?
  • What is the risk of a poor outcome now?
  • What antibiotic(s) should be used now?
  • What is the duration of therapy?
state of the art treatment of staphylococcus aureus bacteremia
“State of the Art” Treatment of Staphylococcus aureus Bacteremia
  • Current armamentarium is inadequate for
    • Out patient treatment
    • MRSA
    • Patients who fail or cannot tolerate therapy
  • Physicians often must rely on
    • Drugs not approved for treatment of complicated staphylococcal infections
    • Drugs of unknown or poorly documented efficacy
    • Second-line agents
    • Combinations of agents of uncertain benefit
slide28

CUBICIN® (daptomycin for injection) for S. aureus Bacteremia Including Those With Known or Suspected Endocarditis

David Mantus, Ph.D.

Vice President, Regulatory AffairsCubist Pharmaceuticals

Adjunct Assistant ProfessorMassachusetts College of Pharmacy

what is daptomycin
What is Daptomycin?
  • Cyclic lipopeptide natural product
  • Approved (IV, 4 mg/kg q24h) for complicated skin and skin structure infections, including MRSA
    • US 2003
    • Israel 2004
    • Argentina 2005
    • EU 2006
post licensure experience
Post-licensure Experience
  • 150,000+ patients treated
    • No new toxicities
    • ~1/3 of doses delivered in outpatient setting
  • Potency vs. S. aureus maintained
    • Microbiologic surveillance studies demonstrate> 99.9% of isolates are daptomycin susceptible
  • ~25% of use is for bacteremia (off-label)
    • ~50% of this use at the 4 mg/kg dose approved for skin, NOT the 6 mg/kg dose studied in S. aureus bacteremia
rationale for daptomycin in s aureus bacteremia and endocarditis
Rationale for Daptomycin in S. aureus Bacteremia and Endocarditis
  • Rapidly bactericidal in vitro and in vivo
  • Potency against MRSA and MSSA
  • Proven clinical efficacy in skin (MRSA and MSSA)
  • Proven efficacy in animal models of S. aureus endocarditis at 6 mg/kg human equivalent dose
  • Potential for outpatient treatment
    • Monotherapy
    • Once-daily
continuous dialogue with fda on development
Continuous Dialogue with FDA on Development
  • Study design (2001-2002)
    • Open-label
    • Comparators
    • Enrollment of all patients with S. aureus
    • Data Safety Monitoring Board
  • Study assessments and analyses (2004-2005)
    • Adjudication Committee
    • Primary endpoints
    • Statistical Analysis Plan agreed upon prior to unblinding
  • Study results (2005)
    • sNDA filed
    • Priority review granted
s aureus bacteremia and endocarditis supplemental indication and dose
S. aureus Bacteremia and EndocarditisSupplemental Indication and Dose
  • Proposed Indication
    • Staphylococcus aureus bacteremia (SAB) including those with known or suspected endocarditis (SAIE) caused by methicillin-susceptible and methicillin-resistant strains
  • Proposed Dose
    • 6 mg/kg monotherapy administered as a 30-minute intravenous (IV) infusion once per day for a minimum duration of 2 to 6 weeks, depending on theclinical condition
agenda
Agenda

Introduction

David Mantus, Ph.D.V.P. Regulatory AffairsCubist Pharmaceuticals

Efficacy

Helen Boucher, M.D.Assistant Professor of MedicineDir. Infectious Diseases Fellowship ProgramDiv. of Infectious Diseases and Geographic MedicineTufts University-NEMC

Microbiology

Jeff Alder, Ph.D.V.P. Drug Discovery & EvaluationCubistPharmaceuticals

Safety

Gloria Vigliani, M.D.V.P. Medical StrategyCubist Pharmaceuticals

Conclusions

G. Ralph Corey, M.D.Professor of Internal Medicine & Infectious DiseaseDuke University Medical Center

overall findings
Overall Findings

Daptomycin 6 mg/kg once daily:

  • Effective in the treatment of S. aureus bacteremia and endocarditis
    • Response higher in MRSA
  • Well tolerated for extended treatment durations
  • Less nephrotoxic than standard-of-care agents
  • Provides a much needed option for treatment of patients with S. aureus bacteremia including those with known or suspected endocarditis